Eli Lilly (NYSE: LLY) has been around for almost 150 years, finding ways to innovate and grow. The next largest healthcare ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly and Co. has begun selling its blockbuster weight-loss and diabetes drug Mounjaro in India, pipping rivals in a ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The much-awaited launch of Mounjaro, an injectable drug used to treat obesity, overweight, and type 2 diabetes, has been ...

Eli Lilly launches diabetes and obesity drug Mounjaro in India, offering innovative treatment for metabolic health management ...

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India after receiving regulatory approval. With rising ...

Eli Lilly (LLY) stock in focus as the company launches its weight loss therapy Mounjaro in India, beating its rival Novo Nordisk (NVO). Read more here.

Eli Lilly's stock is undervalued; defensive healthcare stocks shine amid uncertainty, and Eli Lilly drives growth. Click here ...

Once-a-weekly, prescription-based medicine, Mounjaro is a single molecule that selectively binds to and activates both GIP ...